Evidence map›Paper›PMID 21471134›Full record

Trial reportEuropean heart journal2011

Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study.

José R Banegas, Esther López-García, Jean Dallongeville, Eliseo Guallar, Julian P Halcox, Claudio Borghi, Elvira L Massó-González, Francisco J Jiménez, Joep Perk, Philippe Gabriel Steg and 2 more

Registry-linked trialOpen access · greenAbstract readClinical TrialMulticenter Study
In one paragraph

Trial report in European heart journal, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02314663 (Effectiveness of a Combined Strategy to Improve Therapeutic Compliance and Degree of Control Among Patients With Hypercholesterolaemia), which is not on this map. Cited by 113 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
113citing papers in PubMed, 3 pooled it
24.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02314663 naunknown statusnot on this mapstarted 2013, after this paper: background citation

Effectiveness of a Combined Strategy to Improve Therapeutic Compliance and Degree of Control Among Patients With Hypercholesterolaemia: a Randomised Clinical Trial

TypeinterventionalSponsorGerencia de Atención Primaria, AlbaceteRan2013 to 2015Enrolled358ConditionsHypercholesterolemia, Medication Adherence, Primary Health CareArms"COMBINED STRATEGY"
3 · Its place in the literature

Who cites it

113 citing papers in PubMed, 3 syntheses or guidelines pooled it, 355 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Guideline
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Article

53 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 9 institutions in 7 countries.

José R BanegasDepartment of Preventive Medicine and Public Health, School of Medicine, Universidad Autónoma de Madrid/IdiPAZ, Avda Arzobispo Morcillo 2, Madrid, Spain. joseramon.banegas@uam.es
Esther López-García
Jean Dallongeville
Eliseo Guallar
Julian P Halcox
Claudio Borghi
Elvira L Massó-González
Francisco J Jiménez
Joep Perk
Philippe Gabriel Steg
Guy De Backer
Fernando Rodríguez-Artalejo
Inserm · FRUniversidad Autónoma de Madrid · ESAstraZeneca (Spain) · ESCardiff University · GBCentro de Investigación Biomédica en Red de Epidemiología y Salud Pública · ESGhent University · BELinnaeus University · SESpanish National Centre for Cardiovascular Research · ESUniversity of Bologna · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsMost studies on the primary prevention of cardiovascular disease (CVD) have been limited to patients at high CVD risk. We assessed the achievement of treatment goals for CVD risk factors among patients with a substantial variation in CVD risk. METHODS AND

resultsThis study was conducted with 7641 outpatients aged ≥50 years, free of clinical CVD and with at least one major CVD risk factor, selected from 12 European countries in 2009. Risk factor definition and treatment goals were based on the 2007 European guidelines on CVD prevention. Cholesterol fractions and glycated haemoglobin (HbA1c) were measured in a central laboratory. Cardiovascular disease risk was estimated with the SCORE equation. Patients' mean age was 63 years (48% men), and 40.1% had a high CVD risk. Among treated hypertensives (94.2%), only 38.8% achieved the blood pressure target of <140/90 mmHg [between-country range (BCR): 32.1-47.5%]. Among treated dyslipidaemic patients (74.4%), 41.2% attained both the total- and LDL-cholesterol target of <5 and <3 mmol/L, respectively (BCR: 24.3-68.4%). Among treated type 2 diabetic patients (87.2%), 36.7% achieved the <6.5% HbA1c target (BCR: 23.4-48.4%). Among obese patients on non-pharmacological treatment (92.2%), 24.7% reached the body mass index target of <30 kg/m(2) (BCR: 12.7-37.1%). About one-third of controlled patients on treatment were still at high remaining CVD risk. Although most patients were advised to reduce excess weight and to follow a low-calorie diet, less than half received written recommendations.

conclusionsIn Europe, a large proportion of patients in primary prevention have CVD risk factors that remain uncontrolled, and lifestyle counselling is not well implemented; moreover, there is substantial between-country variation, which indicates additional room for improvement. Raised residual CVD risk is relatively frequent among patients despite control of their primary risk factors and should be addressed.

Indexed as

AgedCardiovascular DiseasesCross-Sectional StudiesDiabetes Mellitus, Type 2DyslipidemiasFemaleHumansHypertensionHypoglycemic AgentsHypolipidemic AgentsLipidsMaleMiddle AgedObesityPrimary PreventionRisk FactorsHypoglycemic AgentsHypolipidemic AgentsLipids

Identifiers

PMID21471134
PMCPMC3164103
OpenAlexW2096318148

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.